The number of medicines prescribed for ADHD rose by 8% in the last quarter of 2024, the latest NHS figures show.
Between October and December there were 870,000 prescription items for ADHD in England, showing a continuing upward trend.
The number of identified patients prescribed the medicines also increased by 6.1% to 248,000 compared with the previous quarter, the figures from the NHS Business Services Authority show, with costs of the drugs also increasing by 7.9%.
In September, researchers warned that regional variation on shared-care arrangements for ADHD medicine prescribing must be addressed to ensure equitable access.
NHS England had announced a new ADHD taskforce to improve care for people living with the condition.
In 2023/24 there had been a 28% increase in the number of ADHD drugs prescribed for adults, NHS BSA had said.
Prescriptions for antidepressants have also continued to rise albeit at a much lower level, the latest quarterly figures from the NHS Business Services Authority show.
Between October and December 2024 there were 24 million depressant items prescribed to seven million patients.
It is a rise of around 1% in both prescriptions and the number of people taking the medicines, the figures show.
But the cost of prescribing the drugs fell by around 6.4%.
The report shows the NHS has prescribed 24 million antidepressant drugs (an increase of 1.6%) to an estimated seven million identified patients (an increase of 1%). The cost of antidepressant drugs to £57 million. This was a 6.4% decrease.
Drugs for dementia also increased by 2% to 1.2 million items, prescribed to 273,000 patients. This drug group had the largest growth in cost when compared to the other BNF medicine groups, increasing by 15%, the figures showed.
The number of hypnotics and anxiolytics prescribed increased by 1.4% to 3.4 million items, with patients increasing by 1% to 1 million.
Drugs used in psychoses and related disorders reached 3.5 million items prescribed to 664,000 identified patients, which is an increase of 1.1%.
A version of this article was first published by our sister title Pulse
Keep your clinical knowledge up to date with The Pharmacist
Extend your learning and record your learning outcomes
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.